# Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome

> **NCT03383380** · PHASE1,PHASE2 · COMPLETED · sponsor: **Children's Hospital of Fudan University** · enrollment: 30 (actual)

## Conditions studied

- Activated PI3K-delta Syndrome
- Immunodeficiency Primary

## Interventions

- **DRUG:** Rapamycin

## Key facts

- **NCT ID:** NCT03383380
- **Lead sponsor:** Children's Hospital of Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-01
- **Primary completion:** 2022-11-30
- **Final completion:** 2023-11-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03383380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03383380, "Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03383380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*